Status:
COMPLETED
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
Lead Sponsor:
United Therapeutics
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
Brief Summary
This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH). Once enrolled, the pa...
Eligibility Criteria
Inclusion
- Are newly prescribed Tyvaso for the treatment of PAH and plan to initiate therapy
- Are willing and able to be contacted by the patient call center.
Exclusion
- Have previously received Tyvaso.
- Are currently enrolled in an interventional (non-FDA approved) PH clinical trial.
Key Trial Info
Start Date :
January 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
98 Patients enrolled
Trial Details
Trial ID
NCT01799473
Start Date
January 1 2013
End Date
December 1 2014
Last Update
March 24 2015
Active Locations (52)
Enter a location and click search to find clinical trials sorted by distance.
1
The Regents of the University of California
La Jolla, California, United States, 92037
2
UCLA Medical Center
Los Angeles, California, United States, 90095
3
Southern California Permanente
Pasadena, California, United States, 91101
4
Central Coast Chest Consultants
San Luis Obispo, California, United States, 93401